RA Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

RA Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$341M	Sell	8,392,730 -2,035,707	-20%	-$70.2M	2.96%	7
2026 Q1	$328M	Hold	10,428,437	–	–	3.48%	6
2025 Q4	$259M	Hold	10,428,437	–	–	2.65%	11
2025 Q3	$169M	Buy	10,428,437 +525,804	+5%	+$7.46M	2.08%	14
2025 Q2	$130M	Buy	9,902,633 +993,542	+11%	+$14.3M	2.19%	12
2025 Q1	$196M	Hold	8,909,091	–	–	3.27%	7
2024 Q4	$238M	Hold	8,909,091	–	–	3.17%	6
2024 Q3	$238M	Hold	8,909,091	–	–	2.74%	9
2024 Q2	$160M	Hold	8,909,091	–	–	2.12%	15
2024 Q1	$163M	Buy	+8,909,091	New	+$142M	2.07%	11
2022 Q2	–	Sell	-2,613,623	Closed	-$25.4M	–	92
2022 Q1	$25.4M	Hold	2,613,623	–	–	0.55%	51
2021 Q4	$39.9M	Hold	2,613,623	–	–	0.7%	42
2021 Q3	$43.4M	Hold	2,613,623	–	–	0.6%	43
2021 Q2	$55.7M	Hold	2,613,623	–	–	0.89%	35
2021 Q1	$84.9M	Buy	+2,613,623	New	+$84.8M	1.28%	22

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RA Capital Management's EWTX Position: Q2 2026 in Review

RA Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 20% in Q2 2026, selling an estimated $70.2M and leaving 8,392,730 shares worth $341M. The position accounts for 2.96% of the portfolio, ranked #7.

RA Capital Management first reported a position in EWTX in Q1 2021 and has held it in 15 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

RA Capital Management held 8,392,730 shares of Edgewise Therapeutics worth $341M as of Q2 2026.
RA Capital Management sold 2,035,707 Edgewise Therapeutics shares in Q2 2026, an estimated $70.2M.
Edgewise Therapeutics made up 2.96% of RA Capital Management's portfolio in Q2 2026, its #7 holding.
RA Capital Management first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 15 quarters since.
225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.